{"changes":[],"country":"US","description":"Clinical-stage biopharma developing the ALT-100 monoclonal antibody for ARDS and progressive pulmonary fibrosis (interrupting eNAMPT/TLR4 signaling). Targets ARDS, fibrosis, and vascular-leak patient populations and pharma partners. FDA-cleared Phase 2a fibrosis study and PUERTA Phase 2a ARDS data presented in 2026 with NIH STTR support.","domain":"aqualungtherapeutics.com","employees":null,"founded":2014,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":26.881547,"lng":-80.053925,"location":"JUNO BEACH, Florida, USA","name":"AQUALUNG THERAPEUTICS, CORP","rounds":[{"amountQuarantined":false,"amountUsd":3000000,"currency":"USD","date":"2023-09-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-05","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"aqualungtherapeutics-com","sources":[{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-05","status":"attributed","url":null},{"fact":"existence","publisher":"aqualungtherapeutics.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://aqualungtherapeutics.com"},{"fact":"description","publisher":"aqualungtherapeutics.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://aqualungtherapeutics.com"}],"stage":null,"techStack":["Afterpay","Sentry","Squarespace","Squarespace Commerce","Stimulus","parallax.js","Vercel Speed Insights","web-vitals","moment 0","@sentry/browser"],"totalRaisedUsd":3000000,"updatedAt":"2026-05-05"}